Keenova Reports Positive Phase 2 Data for CCH in Plantar Fibromatosis
Event summary
- Keenova presented Phase 2 data for CCH in treating plantar fibromatosis at the ACFAS Annual Meeting on February 24, 2026.
- Study 306 showed long-term safety, efficacy, and durability of CCH in plantar fibromatosis patients.
- Phase 3 trial results are expected mid-2026.
- CCH is not currently FDA-approved for plantar fibromatosis.
The big picture
Keenova's Phase 2 data positions CCH as a potential non-surgical treatment for plantar fibromatosis, a condition with no FDA-approved therapies. The Phase 3 trial results, expected mid-2026, will be critical in determining the drug's regulatory and commercial prospects. The company's focus on rare and unaddressed conditions aligns with broader industry trends toward developing targeted therapies for niche indications.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 results will support an FDA approval for CCH in plantar fibromatosis.
- Market Opportunity
- The potential size of the market for a non-surgical treatment option for plantar fibromatosis.
- Competitive Landscape
- How Keenova's progress compares to other companies developing treatments for fibromatosis conditions.